Low Back Pain - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 93 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Low Back Pain - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Low Back Pain - Pipeline Review, H2 2015', provides an overview of the Low Back Pain's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Low Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Low Back Pain and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Low Back Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Low Back Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Low Back Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Low Back Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Low Back Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Low Back Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Low Back Pain Overview 8
Therapeutics Development 9
Pipeline Products for Low Back Pain - Overview 9
Low Back Pain - Therapeutics under Development by Companies 10
Low Back Pain - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Low Back Pain - Products under Development by Companies 15
Low Back Pain - Companies Involved in Therapeutics Development 16
Adynxx, Inc. 16
Aestus Therapeutics, Inc. 17
Astellas Pharma Inc. 18
Eli Lilly and Company 19
Frontier Biotechnologies Co., Ltd 20
Grunenthal GmbH 21
Hisamitsu Pharmaceutical Co., Inc. 22
Immune Pharmaceuticals Inc. 23
Ipsen S.A. 24
MEDRx Co., Ltd. 25
Mesoblast Limited 26
Nektar Therapeutics 27
Orion Oyj 28
Pacira Pharmaceuticals, Inc. 29
Pfizer Inc. 30
Stayble Therapeutics 31
Low Back Pain - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Target 34
Assessment by Mechanism of Action 36
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
(acetaminophen + tramadol hydrochloride) - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
(etodolac + lidocaine) - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
(oxycodone hydrochloride + naltrexone hydrochloride) ER - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
AB-001 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
abobotulinumtoxin A - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ASP-7962 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ATX-09002 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
AYX-2 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
bupivacaine - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
cebranopadol - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
dexmedetomidine hydrochloride - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Drug for Chronic Low Back Pain - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
duloxetine hydrochloride DR - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
HP-3150 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
lidocaine hydrochloride - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
MPC-06ID - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
NKTR-181 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
tanezumab - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
zoledronic acid - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Low Back Pain - Recent Pipeline Updates 74
Low Back Pain - Dormant Projects 87
Low Back Pain - Discontinued Products 88
Low Back Pain - Product Development Milestones 89
Featured News & Press Releases 89
Feb 25, 2015: Nektar Announces Start of Phase 3 SUMMIT-07 Study of NKTR-181 in Patients with Chronic Low Back Pain 89
Jan 23, 2014: Pfizer Reports Top-Line Results from ALO-02 Phase 3 Study 90
Jul 06, 2012: Lilly Obtains Six Months US Pediatric Exclusivity for Cymbalta 90
Feb 03, 2010: Eli Lilly Reports Cymbalta Significantly Reduced Chronic Low Back Pain In A New Study 90
Appendix 92
Methodology 92
Coverage 92
Secondary Research 92
Primary Research 92
Expert Panel Validation 92
Contact Us 92
Disclaimer 93

List of Tables

Number of Products under Development for Low Back Pain, H2 2015 9
Number of Products under Development by Companies, H2 2015 11
Comparative Analysis by Late Stage Development, H2 2015 12
Comparative Analysis by Clinical Stage Development, H2 2015 13
Comparative Analysis by Early Stage Development, H2 2015 14
Products under Development by Companies, H2 2015 15
Low Back Pain - Pipeline by Adynxx, Inc., H2 2015 16
Low Back Pain - Pipeline by Aestus Therapeutics, Inc., H2 2015 17
Low Back Pain - Pipeline by Astellas Pharma Inc., H2 2015 18
Low Back Pain - Pipeline by Eli Lilly and Company, H2 2015 19
Low Back Pain - Pipeline by Frontier Biotechnologies Co., Ltd, H2 2015 20
Low Back Pain - Pipeline by Grunenthal GmbH, H2 2015 21
Low Back Pain - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2015 22
Low Back Pain - Pipeline by Immune Pharmaceuticals Inc., H2 2015 23
Low Back Pain - Pipeline by Ipsen S.A., H2 2015 24
Low Back Pain - Pipeline by MEDRx Co., Ltd., H2 2015 25
Low Back Pain - Pipeline by Mesoblast Limited, H2 2015 26
Low Back Pain - Pipeline by Nektar Therapeutics, H2 2015 27
Low Back Pain - Pipeline by Orion Oyj, H2 2015 28
Low Back Pain - Pipeline by Pacira Pharmaceuticals, Inc., H2 2015 29
Low Back Pain - Pipeline by Pfizer Inc., H2 2015 30
Low Back Pain - Pipeline by Stayble Therapeutics, H2 2015 31
Assessment by Monotherapy Products, H2 2015 32
Assessment by Combination Products, H2 2015 33
Number of Products by Stage and Target, H2 2015 35
Number of Products by Stage and Mechanism of Action, H2 2015 37
Number of Products by Stage and Route of Administration, H2 2015 39
Number of Products by Stage and Molecule Type, H2 2015 41
Low Back Pain Therapeutics - Recent Pipeline Updates, H2 2015 74
Low Back Pain - Dormant Projects, H2 2015 87
Low Back Pain - Discontinued Products, H2 2015 88